Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii

粘菌素 鲍曼不动杆菌 舒巴坦钠 微生物学 碳青霉烯 不动杆菌 多粘菌素 抗生素 医学 生物 药理学 抗生素耐药性 细菌 铜绿假单胞菌 亚胺培南 遗传学
作者
Xingchen Bian,Xiaofen Liu,Meiqing Feng,Phillip J. Bergen,Jian Li,Yuancheng Chen,Huajun Zheng,Sichao Song,Jing Zhang
出处
期刊:International Journal of Antimicrobial Agents [Elsevier]
卷期号:57 (2): 106271-106271 被引量:11
标识
DOI:10.1016/j.ijantimicag.2020.106271
摘要

Aims: Polymyxin-based combination therapy is often used to treat carbapenem-resistant Acinetobacter baumannii (A. baumannii) infections. Although sulbactam is intrinsically active against A. baumannii, few studies have investigated colistin/sulbactam combinations against carbapenem-resistant A. baumannii. Methods: Whole genome sequencing was undertaken on eight carbapenem-resistant (colistin-susceptible) isolates of A. baumannii from Chinese patients. Bacterial killing of colistin and sulbactam, alone and in combination, was examined with checkerboard (all isolates) and static and dynamic time-kill studies (three isolates). In the dynamic studies, antibiotics were administered in various clinically-relevant dosing regimens that mimicked patient pharmacokinetics. Results: The eight isolates consisted of ST195, ST191 and ST208 belonging to clonal complex 208, which is the most epidemic clonal type of A. baumannii globally. All isolates possessed Acinetobacter-derived cephalosporinase (ADC-61 or ADC-78) and seven of eight isolates contained the carbapenem-resistance gene blaOXA-23. The colistin/sulbactam combination was synergistic against two of eight isolates in checkerboard studies. In time-kill studies, rapid bacterial killing of ca. 3–6 log10 CFU/mL was observed with colistin monotherapy, followed by steady regrowth. Sulbactam monotherapy was generally ineffective. Substantially enhanced bacterial killing was observed with colistin/sulbactam combinations in both static and dynamic models, especially with the higher sulbactam concentration (2 g) and/or longer sulbactam infusion time (2 hours) in the dynamic model. Conclusions: This study was the first to use a pharmacokinetics/pharmacodynamics model to investigate synergistic activity of colistin/sulbactam combinations against A. baumannii. It showed that clinically-relevant dosing regimens of colistin combined with sulbactam may substantially improve bacterial killing of multidrug-resistant and carbapenem-resistant A. baumannii.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小怪兽完成签到 ,获得积分10
3秒前
6秒前
倒霉兔子完成签到,获得积分10
8秒前
光溜溜的大门牙完成签到,获得积分10
8秒前
黄橙子完成签到 ,获得积分10
9秒前
11秒前
义气严青完成签到,获得积分10
12秒前
13秒前
13秒前
nalan发布了新的文献求助10
13秒前
恢复出厂设置完成签到 ,获得积分10
14秒前
liwanshu完成签到,获得积分10
14秒前
大橘完成签到 ,获得积分10
14秒前
东子发布了新的文献求助10
16秒前
兜兜揣满糖完成签到 ,获得积分10
17秒前
liwanshu发布了新的文献求助10
19秒前
KissesU完成签到 ,获得积分10
20秒前
打打应助柚子皮蛋瘦肉粥采纳,获得10
22秒前
雨落瑾年完成签到 ,获得积分10
23秒前
所所应助朴素的芹采纳,获得10
24秒前
nalan完成签到,获得积分20
26秒前
无聊的从霜完成签到 ,获得积分10
28秒前
33秒前
CX330完成签到,获得积分10
35秒前
38秒前
执玉笛完成签到,获得积分10
38秒前
46秒前
共享精神应助科研通管家采纳,获得10
51秒前
CipherSage应助科研通管家采纳,获得10
51秒前
桐桐应助科研通管家采纳,获得10
51秒前
天天快乐应助科研通管家采纳,获得10
51秒前
丘比特应助科研通管家采纳,获得10
51秒前
Lucas应助科研通管家采纳,获得10
51秒前
51秒前
sunshine应助科研通管家采纳,获得10
51秒前
FashionBoy应助科研通管家采纳,获得10
51秒前
别惹小熊完成签到,获得积分10
52秒前
59秒前
ZW发布了新的文献求助10
59秒前
adhere发布了新的文献求助10
1分钟前
高分求助中
请在求助之前详细阅读求助说明!!!! 20000
Sphäroguß als Werkstoff für Behälter zur Beförderung, Zwischen- und Endlagerung radioaktiver Stoffe - Untersuchung zu alternativen Eignungsnachweisen: Zusammenfassender Abschlußbericht 1500
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
Yuwu Song, Biographical Dictionary of the People's Republic of China 700
[Lambert-Eaton syndrome without calcium channel autoantibodies] 520
The Three Stars Each: The Astrolabes and Related Texts 500
india-NATO Dialogue: Addressing International Security and Regional Challenges 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2469786
求助须知:如何正确求助?哪些是违规求助? 2136964
关于积分的说明 5444782
捐赠科研通 1861323
什么是DOI,文献DOI怎么找? 925709
版权声明 562721
科研通“疑难数据库(出版商)”最低求助积分说明 495146